Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Avonex in Early HTLV-1-Associated Myelopathy
NCT00001785Phase 2Completed
- Sponsor
- National Institute of Neurological Disorders and Stroke
- Start
- Sep 1998
- Modality
- Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of interferon beta-1a in HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP), sponsored by National Institute of Neurological Disorders and Stroke. Started Sep 1998; status: completed.
02
Drugs
interferon beta-1a
03
Conditions
HTLV-1 associated myelopathy/tropical spastic paraparesis (HAM/TSP)
Beyond the preview
Go deeper on NCT00001785.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00001785.